Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 3,452 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Colorectal Cancer Clear all

Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Ovarian Neoplasms
Interventions: RO7515629, tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Denver, Colorado • Nashville, Tennessee

Conditions: Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
Interventions: CUE-102; Drug
Lead sponsor: Cue Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more

Conditions: Breast Cancer, Colorectal Cancer, Prostate Cancer, Head and Neck Cancer, Lung Cancer
Interventions: Telephone interview or self report survey.; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Metastatic Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions: Quell, Sham Quell; Device
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Colorectal Cancer
Interventions: Not listed
Lead sponsor: Universal Diagnostics; Industry
Eligibility: 45 Years to 84 Years
Enrollment: 6,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lake Barrington, Illinois

Conditions: Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors
Interventions: CDX-585; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Celebration, Florida • New York, New York + 1 more

Conditions: Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor, Chordoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Hepatocellular Carcinoma, Classical Hodgkin Lymphoma, Colorectal Cancer, MTOR Activating Mutation
Interventions: Nab-Rapamycin, Nivolumab; Drug · Biological
Lead sponsor: Sarcoma Oncology Research Center, LLC; Other
Eligibility: 12 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: Bevacizumab, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Sorafenib Tosylate; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Cancer of Colon, Cancer of Rectum
Interventions: Colorectal Health Research Champions; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 30 Years to 99 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Lung Cancer, Breast Cancer, Colon Cancer, Bladder Cancer, Hepatocellular Cancer
Interventions: SAFER TRACKS Intervention; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Houston, Texas • White River Junction, Vermont

Conditions: Behavior, Health
Interventions: Post-visit patient messaging; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 3,888 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer
Interventions: 124I-NM404; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
Interventions: NUC-3373 + leucovorin, NUC-3373, NUFOX, NUFOX + VEGF pathway inhibitor, NUFOX + EGFR inhibitor, NUFIRI, NUFIRI + VEGF pathway inhibitor, NUFIRI + EGFR inhibitor, NUC-3373 + bevacizumab; Drug
Lead sponsor: NuCana plc; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 6
States / cities: Boston, Massachusetts • Durham, North Carolina • Nashville, Tennessee + 2 more

Conditions: Liver Metastasis, Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastasis
Interventions: Talaporfin sodium (LS11), LED-based light infusion device, Light emitting diodes (LED), Photodynamic therapy, Phototherapy, Chemotherapy; Drug · Device · Procedure
Lead sponsor: Light Sciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
Interventions: Bevacizumab, Capecitabine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, Radiation Therapy, Therapeutic Conventional Surgery; Biological · Drug · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 107
States / cities: Birmingham, Alabama • New Britain, Connecticut • Atlanta, Georgia + 66 more

Conditions: Colo-rectal Cancer, Polyp of Colon, Adenomatous Polyp of Colon
Interventions: Use of EverLift, Without use of EverLift; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Low Anterior Resection, Proctosigmoid Resection, Rectal Cancer
Interventions: Covidien Radial Reload Stapler with Tri-Staple Technology; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Tampa, Florida • Durham, North Carolina • Spokane, Washington

Conditions: Colorectal Adenocarcinoma
Interventions: Blood draw (venipuncture); Other
Lead sponsor: Clinical Genomics Pathology; Industry
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 12
States / cities: Redondo Beach, California • Dover, Delaware • Chicago, Illinois + 9 more

Conditions: Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Carcinoma
Interventions: Binimetinib, Palbociclib, Trifluridine and Tipiracil Hydrochloride; Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 7
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Wichita, Kansas + 4 more

Conditions: Gastrointestinal Microbiome, Neoplasm, Colorectal
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer
Interventions: VE800, Nivolumab, Vancomycin Oral Capsule; Biological · Drug
Lead sponsor: Vedanta Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 18
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 13 more

Conditions: Metastatic Colorectal Cancer
Interventions: Cetuximab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 12
States / cities: Duarte, California • Tampa, Florida • Baltimore, Maryland + 9 more

Conditions: Chemotherapeutic Agent Toxicity, Colorectal Cancer, Diarrhea
Interventions: calcium aluminosilicate anti-diarrheal, placebo; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Portland, Oregon • Houston, Texas

Conditions: Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
Interventions: navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy; Biological
Lead sponsor: OncXerna Theraputics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Hot Springs, Arkansas • Los Angeles, California • Tampa, Florida + 5 more

Search by objective public record fields.

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Pain in Cancer Survivors

Quell Opioid Reduction and Pain Relief in Patients With Cancer

Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance

A Study of CDX-585 in Patients With Advanced Malignancies

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer

Colorectal Health Research Champions

Measuring and Improving the Safety of Test Result Follow-Up

Colorectal Cancer Screening Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters

Study of 124I-NM404 in Advanced Solid Malignancies

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm

Radial Reload Open LAR Case Series

Colvera for Detection of Disease Recurrence

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Gut Microbiome in Colorectal Cancer

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors